Akari Therapeutics PLC(AKTX) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. The company is conducting Phase Ib clinical trial of Coversin. The company focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.

Current Price

$1.81

RSI

8.742

Beta:

1.226696

September 30, 2020
-704.2K

-102.004 %
-100.938 %

$0
$0
$0
$0
$0
%
%
%
%

$-17,105,791
$-16,466,780
$-35,399,257
$-18,140,997
$-45,317,530
-3.736 %
114.974 %
-48.753 %
149.807 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.